GlaxoSmithKline (GSK) Receives “Neutral” Rating from JPMorgan Chase & Co.

GlaxoSmithKline (NYSE:GSK)‘s stock had its “neutral” rating reiterated by analysts at JPMorgan Chase & Co. in a report issued on Monday.

A number of other brokerages also recently issued reports on GSK. Zacks Investment Research downgraded GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Wednesday, January 10th. Investec downgraded GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Monday, November 6th. TheStreet upgraded GlaxoSmithKline from a “c+” rating to a “b” rating in a research report on Wednesday, October 25th. ValuEngine downgraded GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Friday. Finally, Bank of America downgraded GlaxoSmithKline from a “buy” rating to a “neutral” rating in a research report on Thursday, October 26th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $38.57.

Shares of GlaxoSmithKline (GSK) opened at $37.10 on Monday. The company has a debt-to-equity ratio of 2.96, a current ratio of 0.64 and a quick ratio of 0.44. GlaxoSmithKline has a 12-month low of $34.52 and a 12-month high of $44.53. The stock has a market capitalization of $91,969.94, a price-to-earnings ratio of 30.41, a P/E/G ratio of 2.30 and a beta of 0.98.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Fisher Asset Management LLC increased its stake in GlaxoSmithKline by 2.3% in the third quarter. Fisher Asset Management LLC now owns 12,828,251 shares of the pharmaceutical company’s stock valued at $520,827,000 after acquiring an additional 293,866 shares during the last quarter. Hotchkis & Wiley Capital Management LLC increased its stake in GlaxoSmithKline by 7.3% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 8,416,927 shares of the pharmaceutical company’s stock valued at $341,727,000 after acquiring an additional 569,600 shares during the last quarter. NWQ Investment Management Company LLC increased its stake in GlaxoSmithKline by 9.4% in the third quarter. NWQ Investment Management Company LLC now owns 2,728,458 shares of the pharmaceutical company’s stock valued at $110,775,000 after acquiring an additional 233,689 shares during the last quarter. Ameriprise Financial Inc. increased its stake in GlaxoSmithKline by 7.1% in the third quarter. Ameriprise Financial Inc. now owns 1,855,142 shares of the pharmaceutical company’s stock valued at $75,028,000 after acquiring an additional 122,634 shares during the last quarter. Finally, Hamlin Capital Management LLC increased its stake in GlaxoSmithKline by 0.4% in the third quarter. Hamlin Capital Management LLC now owns 1,772,997 shares of the pharmaceutical company’s stock valued at $71,984,000 after acquiring an additional 7,882 shares during the last quarter. 9.66% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This news story was originally published by American Banking News and is the property of of American Banking News. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/05/glaxosmithkline-gsk-receives-neutral-rating-from-jpmorgan-chase-co.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply